• Explore /
  • Poster
  • / Updated overall survival (OS) analysis for ProCAID: A randomized, double-blind, placebo-controlled phase II trial of capivasertib with docetaxel versus docetaxel alone in metastatic castration-resistant prostate cancer (mCRPC).

Updated overall survival (OS) analysis for ProCAID: A randomized, double-blind, placebo-controlled phase II trial of capivasertib with docetaxel versus docetaxel alone in metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Simon J. Crabb

Southampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom

Simon J. Crabb , Gareth Owen Griffiths , Denise Dunkley , Nichola Downs , Mary Ellis , Mike Radford , Michelle Light , Josh Northey , Amy Whitehead , Sam Wilding , Claire Rooney , Carolina Salinas-Souza , Alison Jane Birtle , Vincent Khoo , Robert J. Jones

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02121639

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr 108)

DOI

10.1200/JCO.2022.40.6_suppl.108

Abstract #

108

Poster Bd #

F4

Abstract Disclosures

Similar Posters

First Author: Simon J. Crabb

First Author: Maral DerSarkissian

First Author: Adam McLain Kase

First Author: Kim van der Zande